The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ITRM | -80.84% | -97.75% | -53.18% | -100% |
| S&P | +15.66% | +86.6% | +13.29% | +154% |
Iterum Therapeutics Plc operates as a pharmaceutical company, which engages in the development and commercialization of sulopenem. The company was founded by Corey N. Fishman on June 24, 2015 and is headquartered in Dublin, Ireland.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $390.00K | 0.0% |
| Gross Profit | $15.00K | 287.5% |
| Gross Margin | 3.85% | 0.0% |
| Market Cap | $29.92M | 20.9% |
| Market Cap / Employee | $3.32M | 0.0% |
| Employees | 9 | -35.7% |
| Net Income | -$8,979.00K | -47.3% |
| EBITDA | -$7,376.00K | -51.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $11.00M | -17.9% |
| Accounts Receivable | $448.00K | 0.0% |
| Inventory | 1.1 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $33.45M | 283.3% |
| Short Term Debt | $281.00K | -98.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -111.35% | -1.5% |
| Return On Invested Capital | -8.21% | -192.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$7,860.18K | -163.2% |
| Operating Free Cash Flow | -$7,847.61K | -162.8% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -3.49 | -9.50 | -13.90 | -7.26 | 338.43% |
| Price to Sales | 78.69 | - | |||
| Price to Tangible Book Value | -3.49 | -1.63 | -1.62 | -1.23 | -25.73% |
| Enterprise Value to EBITDA | -20.16 | -18.23 | -11.45 | -7.24 | 17.59% |
| Return on Equity | -355.4% | -555.7% | - | ||
| Total Debt | $45.60M | $32.05M | $32.56M | $33.74M | 48.59% |
No podcast episodes available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
